Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients

ClinicalTrials.gov ID: NCT02151461

Public ClinicalTrials.gov record NCT02151461. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effect of Various Fixed-Dose Leucine and Metformin Combinations (NS-0100) Versus Standard Metformin Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this study is to demonstrate that leucine in combination with a low does of metformin can serve as an adjunct to diet and exercise to improve blood glucose levels in type 2 diabetic subjects. This study will compare three doses of a leucine-metformin combination to the standard metformin dose in controlling blood glucose levels in type 2 diabetic patients.

Study identification

NCT ID
NCT02151461
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
NuSirt Biopharma
Industry
Enrollment
96 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2014
Primary completion
Jul 31, 2015
Completion
Dec 31, 2015
Last update posted
Feb 26, 2018

2014 – 2016

United States locations

U.S. sites
9
U.S. states
6
U.S. cities
8
Facility City State ZIP Site status
Catalina Research Institute Chino California 91710
Palm Beach Research Palm Beach Florida 33409
Meridien Research Tampa Florida 33606
River Birch Research Alliance Blue Ridge Georgia 30513
Meridian Research Savannah Georgia 31406
Streling Research Group Cincinnati Ohio 45219
Medical Research South Charleston South Carolina 29407
Meharry Medical College Nashville Tennessee 37208
Vanderbilt University Medical Center, Diabetes, Endocrinology, and Metabolism Nashville Tennessee 37232

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02151461, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 26, 2018 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02151461 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →